Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Prensa/medios de comunicación

Período13 feb. 2023 → 14 feb. 2023

Cobertura de los medios

17

Cobertura de los medios